US Bancorp’s Aldeyra Therapeutics ALDX Stock Holding History

US Bancorp’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-554	Closed	-$2.89K	–	4042
2025 Q3	$2.89K	Sell	554 -20,582	-97%	-$107K	﹤0.01%	3697
2025 Q2	$81K	Buy	21,136 +21,112	+87,967%	+$54.6K	﹤0.01%	2542
2025 Q1	$138	Buy	+24	New	+$142	﹤0.01%	4125
2024 Q4	–	Sell	-5,578	Closed	-$30.1K	–	4159
2024 Q3	$30.1K	Buy	+5,578	New	+$26.6K	﹤0.01%	2972

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

US Bancorp's ALDX Position: Q4 2025 in Review

US Bancorp sold out of Aldeyra Therapeutics (ALDX) in Q4 2025, closing a stake of 554 shares — an estimated $2.89K sold.

US Bancorp first reported a position in ALDX in Q3 2024 and held it in 4 quarters. The position peaked at $81K in Q2 2025. 136 funds tracked by Wall St. Rank hold ALDX as of Q4 2025.

US Bancorp reported no remaining Aldeyra Therapeutics position as of Q4 2025 after selling out during the quarter.
US Bancorp sold 554 Aldeyra Therapeutics shares in Q4 2025, an estimated $2.89K.
US Bancorp first reported a position in Aldeyra Therapeutics in Q3 2024 and held it in 4 quarters.
US Bancorp's Aldeyra Therapeutics position peaked at $81K in Q2 2025.
136 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2025.

Based on US Bancorp's 13F filing for Q4 2025, filed 30 Jan 2026.